Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 6, 2022
Regulation
May 5 Quick Takes: Turning Point, LaNova in deal for Claudin ADC
Plus AZ’s Farxiga and Ultomiris both meet and updates from Deerfield-Illumina, Argenx, CMS, Janssen and more
BioCentury | Apr 23, 2021
Regulation
Evkeeza for HoFH among April’s CHMP recommendations: Data Byte
April’s recommendations by EMA’s CHMP included a positive opinion for Evkeeza evinacumab from Regeneron to treat homozygous familial hypercholesterolemia, which offers a new mechanism of
BioCentury | Aug 18, 2020
Product Development
Gilead, Tango expand cancer partnership; plus Roche approval, Novavax COVID-19 efficacy study and G1, Myovant and PTC applications under review
Gilead takes stake in Tango, expands 2018 dealGilead Sciences Inc. (NASDAQ:GILD) million has expanded its 2018 deal with Tango Therapeutics Inc. to cover worldwide options over seven years from
BioCentury | Jun 12, 2020
Product Development
June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi
BioCentury | Jan 25, 2020
Product Development
A milestone year for Roche’s CNS gambit could kick off its plan for the decade
Roche putting CNS as the growth driver of the next decade; 2020 might be the year it takes off
BioCentury | Aug 27, 2019
Company News
Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano
BioCentury | Jun 28, 2019
Company News
June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more
BioCentury | May 7, 2019
Clinical News
Viela reports detailed Phase II/III data for rare CNS disorder therapy
BioCentury | Jan 4, 2019
Clinical News
Viela planning BLA submission for inebilizumab in rare CNS disorder
Items per page:
1 - 10 of 23